^
Association details:
Biomarker:ALK mutation + TMB-H
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Source:
Title:

Analysis of correlations between driver mutations and biomarkers with response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC).

Published date:
05/19/2021
Excerpt:
One patient with a BRAF mutation and another patient with an ALK mutation had partial responses (PR); both had TMB ≥ 10....In patients with driver mutations, while PD-L1 expression may not be associated with response to immunotherapy, a high TMB level may be a predictive biomarker...
DOI:
10.1200/JCO.2021.39.15_suppl.e21022